MX2020001725A - Anticuerpos de fijacion a nicotina novedosos. - Google Patents

Anticuerpos de fijacion a nicotina novedosos.

Info

Publication number
MX2020001725A
MX2020001725A MX2020001725A MX2020001725A MX2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A MX 2020001725 A MX2020001725 A MX 2020001725A
Authority
MX
Mexico
Prior art keywords
nicotine
binding antibodies
novel nicotine
novel
treating
Prior art date
Application number
MX2020001725A
Other languages
English (en)
Inventor
Nicola Beltraminelli
Stéphanie Fallot
Matthew W Kalnik
Thomas Thisted
Zuzana Biesova
Steve Fuller
Mark G Lesage
Paul Pentel
Original Assignee
BliNK Biomedical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BliNK Biomedical filed Critical BliNK Biomedical
Publication of MX2020001725A publication Critical patent/MX2020001725A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen anticuerpos de fijación a nicotina novedosos y métodos para usarlos para tratar la adicción a la nicotina y/o facilitar el cese del tabaquismo, o para tratar la sobredosis de nicotina o la intoxicación por nicotina.
MX2020001725A 2017-08-15 2018-08-14 Anticuerpos de fijacion a nicotina novedosos. MX2020001725A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762545696P 2017-08-15 2017-08-15
PCT/US2018/046621 WO2019036419A1 (en) 2017-08-15 2018-08-14 NEW NICOTINE BINDING ANTIBODIES

Publications (1)

Publication Number Publication Date
MX2020001725A true MX2020001725A (es) 2020-08-20

Family

ID=63405495

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001725A MX2020001725A (es) 2017-08-15 2018-08-14 Anticuerpos de fijacion a nicotina novedosos.

Country Status (10)

Country Link
US (2) US11440970B2 (es)
EP (1) EP3668598A1 (es)
JP (1) JP7364555B2 (es)
KR (1) KR102712005B1 (es)
CN (1) CN111432883B (es)
AU (1) AU2018317372A1 (es)
BR (1) BR112020002994A2 (es)
CA (1) CA3072767A1 (es)
MX (1) MX2020001725A (es)
WO (1) WO2019036419A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512549A (zh) * 2018-06-06 2021-03-16 安蒂多特疗法公司 改善循环和治疗心血管疾病的方法
KR102530111B1 (ko) * 2022-03-11 2023-05-10 앱클론(주) 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5444386A (en) 1985-03-08 1986-09-11 Baylor College Of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and polyclonal)
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002058635A2 (en) 2001-01-26 2002-08-01 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
US20050089524A1 (en) 2002-03-01 2005-04-28 Sanderson Sam D. Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
WO2007064478A2 (en) 2005-11-28 2007-06-07 Nabi Biopharmaceuticals Method for making nicotine hapten
WO2007100755A1 (en) 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
EP2319867A1 (en) * 2007-11-29 2011-05-11 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
US8232072B2 (en) 2008-06-13 2012-07-31 Nabi Biopharmaceuticals Smoking cessation kit and method

Also Published As

Publication number Publication date
KR20200089255A (ko) 2020-07-24
EP3668598A1 (en) 2020-06-24
KR102712005B1 (ko) 2024-09-30
US11440970B2 (en) 2022-09-13
CN111432883A (zh) 2020-07-17
US20200377616A1 (en) 2020-12-03
WO2019036419A1 (en) 2019-02-21
JP7364555B2 (ja) 2023-10-18
CN111432883B (zh) 2024-10-01
US20230089068A1 (en) 2023-03-23
CA3072767A1 (en) 2019-02-21
AU2018317372A1 (en) 2020-03-05
BR112020002994A2 (pt) 2020-08-11
JP2020531480A (ja) 2020-11-05

Similar Documents

Publication Publication Date Title
ZA202202559B (en) Kras g12c inhibitors and methods of using the same
MX2020002502A (es) Inhibidores de kras g12c y metodos para utilizarlos.
MY196830A (en) Kras g12c inhibitors and methods of using the same
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX2021005700A (es) Inhibidores de kras g12c y metodos de uso de los mismos.
MX2020010836A (es) Inhibidores de kras g12c y métodos para su uso.
MX2020011582A (es) Inhibidores de kras g12c y metodos para su uso.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX2018010362A (es) Metodos y sistemas para evaluar carga mutacional de tumores.
MX2020000960A (es) Anticuerpos anti-tigit.
ZA201805507B (en) Dry-process reconstituted tobacco leaf, method and device for producing dry-process reconstituted tobacco leaf
MX2019011916A (es) Anticuerpos anti-lag3.
MX2016014189A (es) Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico.
PH12020552229A1 (en) Il-11ra antibodies
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MA39896A (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
MX2017002862A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso.
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
EP3331526A4 (en) NICOTIN-DEGREEING ENZYMES FOR THE TREATMENT OF NICOTINE DEPENDENCE AND NICOTINE POISONING
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.